Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Antiviral Res. 2014 Oct 31;113:49–61. doi: 10.1016/j.antiviral.2014.10.011

Figure 8. Convallatoxin treatment limits CMV production.

Figure 8

MRC5 cells were pretreated with DMSO, 12μM ganciclovir, or 5nM convallatoxin and then infected with AD169IE2-YFP (MOI:0.5). At 1dpi, each respective compound was removed and the cell culture media was replaced. YFP+ cells were measured in 48-hour intervals using an Acumen eX3 cytometer and then supernatant was harvested for titration of infectious extracellular virus using a standard plaque assay. (A) The % infection of ganciclovir-treated cells (filled triangles) and convallatoxin-treated cells (filled squares) was calculated throughout the 9-day timecourse. (B) Day 3, 5, 7, and 9 supernatants from the ganciclovir-treated infection (filled triangles, dotted line) (left panel) or the convallatoxin-treated infection (filled squares, dotted line) (right panel), were plotted together with supernatant from the DMSO-treated infection (filled circles, solid line) (both panels). Error bars represent standard error of the mean.